288 related articles for article (PubMed ID: 34742252)
1. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.
Straube A; Stude P; Gaul C; Schuh K; Koch M
J Headache Pain; 2021 Nov; 22(1):133. PubMed ID: 34742252
[TBL] [Abstract][Full Text] [Related]
2. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
[TBL] [Abstract][Full Text] [Related]
3. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
[TBL] [Abstract][Full Text] [Related]
4. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
6. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
7. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S
Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609
[TBL] [Abstract][Full Text] [Related]
8. A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Becker WJ; Spacey S; Leroux E; Giammarco R; Gladstone J; Christie S; Akaberi A; Power GS; Minhas JK; Mancini J; Rochdi D; Filiz A; Bastien N
Headache; 2022 Apr; 62(4):522-529. PubMed ID: 35403223
[TBL] [Abstract][Full Text] [Related]
9. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
10. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
11. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
12. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
[TBL] [Abstract][Full Text] [Related]
13. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H; Holle D; Nsaka M; Kleinschnitz C; Glas M; Scheffler A
J Headache Pain; 2022 May; 23(1):55. PubMed ID: 35538414
[TBL] [Abstract][Full Text] [Related]
14. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.
Viudez-Martínez A; Pascual-Carrasco A; Beltrán-Blasco I; Hernandez-Lorido R; F Ruiz de Apodaca R
J Clin Pharm Ther; 2022 Jun; 47(6):814-823. PubMed ID: 35212025
[TBL] [Abstract][Full Text] [Related]
16. Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.
Gantenbein AR; Agosti R; Kamm CP; Landmann G; Meier N; Merki-Feld GS; Petersen JA; Pohl H; Ryvlin P; Schankin CJ; Viceic D; Zecca C; Schäfer E; Meyer I; Arzt ME
J Headache Pain; 2022 Nov; 23(1):142. PubMed ID: 36401172
[TBL] [Abstract][Full Text] [Related]
17. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
Eghtesadi M; Leroux E; Pagé G
Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
[TBL] [Abstract][Full Text] [Related]
18. Erenumab for episodic migraine.
Datta A; Gupta S; Maryala S; Aggarwal V; Chopra P; Jain S
Pain Manag; 2022 Jul; 12(5):587-594. PubMed ID: 35313740
[TBL] [Abstract][Full Text] [Related]
19. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence.
Khalil M; Moreno-Ajona D; Villar-Martínez MD; Greenwood F; Hoffmann J; Goadsby PJ
Eur J Neurol; 2022 Aug; 29(8):2473-2480. PubMed ID: 35445471
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
Fernández-Bravo-Rodrigo J; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Flor-García A; Barreda-Hernández D; Pascual-Morena C
Eur J Pharmacol; 2024 Aug; 976():176702. PubMed ID: 38823758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
